BCL2L11 and breast cancer: We found that AS1842856 treatment for 48 h induced FAS and/or BIM gene expression in BT549, MDA‐MB‐468 breast cancer cell lines, and DBTRG, A172 LN229, LN18, and U87MG GBM cell lines (Fig. 3A–F and Fig. S1A).